Ketamine Anesthesia in Electroconvulsive Therapy
Information source: Mayo Clinic
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Depression
Intervention: Ketamine (Drug); methohexital (Drug)
Phase: N/A
Status: Completed
Sponsored by: Mayo Clinic Official(s) and/or principal investigator(s): Keith Rasmussen, MD, Principal Investigator, Affiliation: Mayo Clinic
Summary
Does the use of ketamine as the anesthetic medication in electroconvulsive therapy (ECT)
accelerate the antidepressant effect of ECT?
The study hypothesis was that depressed subjects receiving ECT with ketamine as the
anesthetic agent would demonstrate a faster rate of improvement, defined as lower depression
ratings after the second ECT than depressed patients receiving ECT with the usual anesthetic
agent.
Clinical Details
Official title: A Randomized Comparison of Ketamine and Methohexital Anesthesia for Electroconvulsive Therapy (ECT) in Depression
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Mean Depression Rating Using the Hospital Anxiety and Depression Scale (HADS)
Secondary outcome: Mean Depression Rating Using the Patient Health Questionnaire-9 (PHQ-9)Mean Post Anesthesia Recovery Side Effects
Detailed description:
There are several drugs available to induce anesthesia for electroconvulsive therapy (ECT),
a psychiatric treatment for major depressive illness. The most commonly utilized of these
include methohexital, thiopental, etomidate, and propofol. Recently, there has been interest
in the use of ketamine in sub-anesthetic doses to treat major depressive illness.
In this randomized, blinded trial, depressed subjects scheduled to be treated with ECT were
anesthetized with either ketamine or methohexital at doses of approximately 1. 0 mg/kg for
each drug. Patients received the same drug for up to six of their ECT treatments. Outcome
measures included assessments of depressive severity, cognition, post-anesthesia side
effects, and hemodynamics.
Subjects were to be followed with as long as they were receiving inpatient ECT treatments.
The number of treatments was determined entirely by their primary psychiatric team, also
blind to anesthetic, as per usual care. In other words, this study did not determine when to
terminate the ECT course.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion criteria:
- Diagnosis of depression, either unipolar or bipolar
- Subjects receiving ECT at the Mayo Clinic
Exclusion criteria:
- Subjects not giving their own consent to ECT
- Subjects with schizophrenia, schizoaffective disorder, or dementia
- Subjects diagnosed with a major neurological disorder such as epilepsy, Parkinson
disease, multiple sclerosis, or a neurodegenerative dementia.
Locations and Contacts
Mayo Clinic in Rochester, Rochester, Minnesota 55905, United States
Additional Information
Starting date: May 2011
Last updated: August 5, 2013
|